TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors

NCT07713732 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer ( SCLC )
Neuroendocrine Cancer
Malignant Pleural Mesotheliomas (Mpm)
Synovial Sarcomas

Interventions

DRUG: TLN-499
DRUG: Venetoclax

Sponsor

Treeline Biosciences, Inc.